Description: Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Home Page: www.genmab.com
Kalvebod Brygge 43
Copenhagen,
1560
Denmark
Phone:
45 70 20 27 28
Officers
| Name | Title |
|---|---|
| Dr. Jan G.J. van de Winkel Ph.D. | Co-Founder, Pres & CEO |
| Mr. Anthony Pagano | Exec. VP & CFO |
| Mr. Anthony Mancini | Exec. VP & COO |
| Mr. Martin Schultz | Sr. Director of Clinical Operations & Non-Independent Director |
| Dr. Judith V. Klimovsky M.D. | Exec. VP & Chief Devel. Officer |
| Dr. Tahamtan Ahmadi | Exec. VP, Chief Medical Officer & Head of Experimental Medicines |
| Dr. Mijke Zachariasse Ph.D. | Sr. Director, Head of Antibody Research Materials & Non-Independent Director |
| Mr. Takahiro Hamatani | Sr. Director of Fin. Japan & Non-Independent Director |
| Mr. Andrew Carlsen | Sr. Director, VP & Head of Investor Relations |
| Ms. Birgitte Stephensen M.Sc. | Exec. VP & Chief Legal Officer |
Exchange: IL
Country: GB : United Kingdom of Great Britain and Northern Ireland
Currency: Danish krone (kr)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 14.3885 |
|---|---|
| Trailing PE: | 20.7009 |
| Price-to-Book MRQ: | 2.9725 |
| Price-to-Sales TTM: | 7.1684 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 2015 |